NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered GHK-Cu from Qing Li Peptide? Mail in a sample (US only) and let us test it.

Test my supply
+17 more ↓
86%
Finnrick rating
#76 of 156 GHK-Cu vendors
33 of 38 classifiable tests passed
customers 4.7★ (18)
methodology · Purity focus
Finnrick analysis · GHK-Cu

Qing Li Peptide's GHK-Cu record is mostly passing but not clean, with a recent 98.5% purity miss dragging the rating down. Quantity is volatile too, including a prior -40% result, so the test history matters more than the headline.

methodology →
vendor intelligence report
Vendor Intelligence Report: Qing Li Peptide

Qing Li now presents a closure notice while stale social channels and related storefronts keep the brand reachable. The report follows Hong Kong filings, shared sales-team photos, cloned Norco copy, and payment/refund trails without overstating unresolved ownership.

39 pages6 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cuselected
$0.05
86%
38
2
Tirzepatide
$0.50
81%
46
3
Retatrutide
$0.97
80%
131
4
Ipamorelin
$0.60
71%
17
5
PT-141
-
69%
7
6
Semaglutide
$1.20
67%
3
7
Melanotan II
$0.40
66%
7
8
Cagrilintide
$1.80
54%
4
9
Sermorelin
$5.00
51%
6
10
Survodutide
$3.00
48%
3
11
BPC-157
$0.70
43%
36
12
Tesamorelin
$1.80
38%
25
13
CJC-1295
$1.40
35%
19
14
MOTS-c
$0.45
34%
6
15
TB-500
$1.20
26%
20
16
Epithalon
$0.50
-
0
17
GLOW
-
-
0
18
HGH
-
-
0
19
KLOW
$0.21
-
0
20
KPV
-
-
0
21
NAD+
$0.02
-
0
22
Pinealon
$0.45
-
0
23
SS-31
$0.44
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%10 Jul 2025: 87%16 Jul 2025: 87%16 Jul 2025: 82%16 Jul 2025: 78%16 Jul 2025: 78%4 Aug 2025: 80%4 Aug 2025: 80%21 Aug 2025: 82%21 Aug 2025: 82%4 Sep 2025: 84%8 Sep 2025: 85%20 Sep 2025: 84%23 Sep 2025: 85%3 Oct 2025: 86%21 Oct 2025: 87%23 Oct 2025: 88%7 Nov 2025: 88%17 Nov 2025: 84%25 Nov 2025: 85%17 Dec 2025: 86%6 Jan 2026: 86%6 Jan 2026: 87%26 Jan 2026: 88%2 Feb 2026: 88%4 Feb 2026: 88%18 Feb 2026: 89%2 Mar 2026: 89%2 Mar 2026: 90%4 Mar 2026: 90%18 Mar 2026: 90%18 Mar 2026: 91%13 May 2026: 88%2 Jun 2026: 88%8 Jun 2026: 89%23 Jun 2026: 89%9 Aug 2026: 89%25 Aug 2026: 89%15 Sep 2026: 87%15 Nov 2026: current 86%87%86%86%Jul 25Nov 26
Showing GHK-Cu tests only
Peptide testing

Ordered GHK-Cu from Qing Li Peptide? Mail in a sample (US only) and let us test it.

Test my supply
Qing Li Peptide GHK-Cu test history
COA-backed lab tests
1-10 of 38

About Qing Li Peptide test results from Finnrick

Qing Li Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 15 peptides and 368 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Qing Li Peptide peptides in this dataset are BPC-157 (36 tests), Cagrilintide (4 tests) and CJC-1295 (19 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests. It also includes 1 correction related to this vendor.

Corrections
2026-03-04
Customer update
Sample potency on sample fz959qa was incorrectly captured as 0.10 mg, correct quantity was 10 mg.
Peptide testing

Ordered GHK-Cu from Qing Li Peptide? Mail in a sample (US only) and let us test it.

Test my supply